- Home
- ASC vs RGNX Comparison
ASC vs RGNX Comparison
Compare ASC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- RGNX
- Stock Information
- Founded
- ASC 2010
- RGNX 2008
- Country
- ASC Bermuda
- RGNX United States
- Employees
- ASC N/A
- RGNX N/A
- Industry
- ASC Marine Transportation
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASC Consumer Discretionary
- RGNX Health Care
- Exchange
- ASC Nasdaq
- RGNX Nasdaq
- Market Cap
- ASC 511.3M
- RGNX 459.1M
- IPO Year
- ASC 2013
- RGNX 2015
- Fundamental
- Price
- ASC $11.29
- RGNX $8.36
- Analyst Decision
- ASC Buy
- RGNX Strong Buy
- Analyst Count
- ASC 3
- RGNX 12
- Target Price
- ASC $20.00
- RGNX $36.00
- AVG Volume (30 Days)
- ASC 1.0M
- RGNX 1.1M
- Earning Date
- ASC 11-06-2024
- RGNX 11-06-2024
- Dividend Yield
- ASC 9.63%
- RGNX N/A
- EPS Growth
- ASC 6.23
- RGNX N/A
- EPS
- ASC 3.55
- RGNX N/A
- Revenue
- ASC $422,624,000.00
- RGNX $84,327,000.00
- Revenue This Year
- ASC N/A
- RGNX $2.34
- Revenue Next Year
- ASC N/A
- RGNX $243.67
- P/E Ratio
- ASC $3.12
- RGNX N/A
- Revenue Growth
- ASC N/A
- RGNX N/A
- 52 Week Low
- ASC $10.86
- RGNX $8.06
- 52 Week High
- ASC $23.44
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- ASC 42.16
- RGNX 39.39
- Support Level
- ASC $10.87
- RGNX $8.06
- Resistance Level
- ASC $12.10
- RGNX $10.52
- Average True Range (ATR)
- ASC 0.37
- RGNX 0.69
- MACD
- ASC 0.14
- RGNX -0.12
- Stochastic Oscillator
- ASC 54.84
- RGNX 9.76
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.